Peachtree Investment Partners LLC Has $19.78 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Peachtree Investment Partners LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 7.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,627 shares of the company’s stock after selling 1,984 shares during the quarter. Eli Lilly and Company makes up about 7.4% of Peachtree Investment Partners LLC’s holdings, making the stock its 3rd biggest position. Peachtree Investment Partners LLC’s holdings in Eli Lilly and Company were worth $19,784,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swisher Financial Concepts Inc. grew its position in shares of Eli Lilly and Company by 7.7% during the 4th quarter. Swisher Financial Concepts Inc. now owns 1,187 shares of the company’s stock worth $916,000 after buying an additional 85 shares during the period. Bank of Nova Scotia lifted its stake in Eli Lilly and Company by 94.3% in the fourth quarter. Bank of Nova Scotia now owns 366,407 shares of the company’s stock valued at $282,885,000 after buying an additional 177,831 shares during the period. Shelton Capital Management grew its position in shares of Eli Lilly and Company by 6.1% during the 4th quarter. Shelton Capital Management now owns 17,821 shares of the company’s stock worth $13,758,000 after buying an additional 1,032 shares during the period. Rollins Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Rollins Financial Advisors LLC now owns 1,732 shares of the company’s stock valued at $1,337,000 after acquiring an additional 19 shares during the last quarter. Finally, Rathbones Group PLC raised its position in shares of Eli Lilly and Company by 20.9% in the 4th quarter. Rathbones Group PLC now owns 189,746 shares of the company’s stock valued at $146,484,000 after acquiring an additional 32,850 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a report on Thursday, March 6th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Citigroup reduced their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Down 2.2 %

Shares of LLY opened at $722.03 on Tuesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm’s 50 day moving average is $846.64 and its 200-day moving average is $830.05. The stock has a market capitalization of $684.61 billion, a PE ratio of 61.66, a P/E/G ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has initiated a share buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.